AbbVie (NYSE:ABBV) Issues Q1 2026 Earnings Guidance

AbbVie (NYSE:ABBV) updated its first quarter 2026 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.970-3.010 for the period, compared to the consensus earnings per share estimate of 3.110. The company issued revenue guidance of $14.7 billion-$14.7 billion, compared to the consensus revenue estimate of $15.0 billion. AbbVie also updated its FY 2026 guidance to 14.370-14.570 EPS.

AbbVie Stock Down 3.8%

Shares of ABBV stock traded down $8.62 during trading hours on Wednesday, hitting $217.04. 15,291,947 shares of the company’s stock traded hands, compared to its average volume of 7,605,424. AbbVie has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market cap of $383.59 billion, a PE ratio of 164.42, a price-to-earnings-growth ratio of 0.93 and a beta of 0.35. The stock’s 50 day simple moving average is $223.99 and its 200 day simple moving average is $219.14.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $16.62 billion during the quarter, compared to analyst estimates of $16.39 billion. During the same period last year, the company earned $2.16 EPS. AbbVie’s revenue for the quarter was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities research analysts expect that AbbVie will post 12.31 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on ABBV. Evercore ISI reaffirmed an “outperform” rating and issued a $228.00 price objective on shares of AbbVie in a research note on Wednesday. Guggenheim boosted their target price on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. DZ Bank cut shares of AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price target on the stock. in a research report on Tuesday, November 4th. Cantor Fitzgerald set a $250.00 price objective on AbbVie and gave the stock an “overweight” rating in a research report on Thursday, October 9th. Finally, UBS Group reissued a “neutral” rating on shares of AbbVie in a research note on Tuesday, January 13th. Two analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $251.50.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q4 beat and raised guidance — AbbVie reported adjusted Q4 EPS of $2.71 and revenue of $16.62B (both above consensus) and guided FY‑2026 adjusted EPS to $14.37–$14.57, underpinning near‑term earnings visibility. AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results
• Positive Sentiment: Immunology momentum — Skyrizi and Rinvoq drove double‑digit growth in the immunology portfolio and helped lift overall revenue ~10% YoY; management says newer immunology sales helped beat expectations. AbbVie forecasts 2026 profit above estimates on strong sales of newer immunology drugs
• Positive Sentiment: Pipeline expansion — AbbVie filed regulatory applications for Rinvoq (upadacitinib) in vitiligo, which would expand indications and provide additional growth optionality if approved. AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®)
• Neutral Sentiment: Analyst positioning mixed but not uniformly negative — some firms (Evercore/others) maintain bullish views citing immunology momentum and neurology upside, supporting longer‑term conviction. AbbVie Buy Thesis Anchored by Robust Immunology Momentum, Neurology Upside, and Long-Term IBD Defense
• Neutral Sentiment: Some commentators view the selloff as a buying opportunity given fundamentals and dividend/institional support, so technical buyers may step in at these levels. MarketBeat AbbVie coverage
• Negative Sentiment: Aesthetics and filler weakness — Allergan/Aesthetics (Botox/Juvederm) showed softer results and investor focus on “filler” weakness pressured the stock despite the companywide beat. AbbVie stock slides as investors focus on aesthetics weakness
• Negative Sentiment: Diversification concerns and a downgrade — some analysts question growth durability outside immunology as oncology and aesthetics declined, and one downgrade highlighted reliance on M&A and the exclusion of IPR&D/milestone costs from guidance. AbbVie’s Immunology Fortress Can’t Hide Cracks In Diversification (Downgrade)
• Negative Sentiment: Profit‑taking despite beat — commentary notes that Rinvoq and some oncology lines missed investor expectations and management excluded acquired IPR&D/milestone impacts from guidance, keeping uncertainty around 2026 cash/earnings assumptions. This helped trigger the selloff. AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat ’26 View

Institutional Trading of AbbVie

Several hedge funds have recently bought and sold shares of ABBV. Brighton Jones LLC raised its holdings in shares of AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after purchasing an additional 3,401 shares during the period. Revolve Wealth Partners LLC increased its position in AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after buying an additional 3,064 shares during the last quarter. Schnieders Capital Management LLC. increased its position in AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company’s stock worth $3,056,000 after buying an additional 789 shares during the last quarter. Ieq Capital LLC raised its stake in shares of AbbVie by 4.6% in the second quarter. Ieq Capital LLC now owns 120,035 shares of the company’s stock valued at $22,281,000 after buying an additional 5,274 shares during the period. Finally, Worldquant Millennium Advisors LLC lifted its position in shares of AbbVie by 117.3% during the 2nd quarter. Worldquant Millennium Advisors LLC now owns 1,135,034 shares of the company’s stock valued at $210,685,000 after buying an additional 612,702 shares during the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.